Jessica zucman-rossi
  • E-mail :[email]
  • Phone : +33 1 53 72 51 66
  • Location : Paris, France
Last update 2020-10-04 08:03:58.43

Jessica zucman-rossi Professor in Oncology, MD, PhD

Course and current status

Director of the Centre de Recherche des Cordeliers, UMRS1138, Inserm, Sorbonne Université, Université de Paris (2019-2023) and of the team « Functional Genomics of Solid Tumors, FunGeST »

Professor of Medicine (PU-PH), Université de Paris-Hôpital Européen Georges Pompidou, AP-HP, Oncology department.

President of the International Liver Cancer Association (ILCA)

Vice-Chair of the SIG Hepatobiliary neoplasia at AASLD

Editor in chief of JHEP Reports (2019-2023), the new gold open access journal of EASL.


  • 1990    Doctor in Medicine, University Paris 7, France
  • 1994    Specialization in Internal Medicine (AIHP)
  • 1994    PhD in life science, Fundamental Basis of Oncogenesis, University Paris 7
  • 1998    Agreement for Research Direction (HDR), University Paris 7

Postgraduate Education

1987-1994: Resident in Internal Medicine, Hopitaux de Paris, in alternation with PhD. 1994‑1996: Post-doctoral research Fellow in Genetic-Oncology, Institut Curie (Director: Gilles Thomas)

Past Editorial Activities

  • Associate editor Journal of Hepatology (2009-2014), Senior editor (2014-2019)
  • Editorial board of Hepatology (2009-2011), Journal of Hepatology (2005-2008), Word Journal of Gastroenterology (2005-2007), GCB (2010-)

Expertise for research projects and funding for national and international institutions: Chairman of the scientific committee CSS2 at Inserm “Genetic, Epigenetic and Cancer” 2012-2016; AERES (Chair, IPC Marseille 2011), AFEF, ANR, ANRS, membre CSS4 (2007-2010), Centre national de séquençage (CNS), Clinique de la souris, CNRS, Conseil général d’Aquitaine, INCa, recherche translationnelle PRTK (chair 2008-2009), Inserm, Ligue nationale contre le cancer (LNCC), Ministère de la Recherche Français, ligue contre le cancer, Université Paris Descartes, Fondation IGR (Chair 2009-2011), Fondation de France, ARC comité tumeurs (2011-2013), SAB du CRCL et CBL (2018)

ERC advanced, Association Anglaise de recherche contre le cancer (AICR) ; Association Italienne de Recherche Contre le cancer (AIRC) ; BMRC Singapour, Dutch Digestive Foundation, NCCS NUHS SMC (Singapore), Cancer Research UK ; United States-Israel Binational Science Foundation (BSF) ; Dutch Cancer Society ; FWF (Austria), Gouvernement chinois de Hong Kong ; the Croucher Foundation (HK) ; Israel Science Foundation (ISF) ; K.U. Leuven, Belgique ; Ministère de la Recherche italien ; Mount Sinai school of medicine ; Swiss National Science Foundation ; Swiss Cancer League, WELBIO (BE) ; ERC (EU) ; MD Anderson (US), HBMS (Singapore).

Scientific Awards and distinctions:

  • Docteur Honoris Causa Université Catholique de Louvain 2019
  • Ismar Boas Medal 2019
  • Chevalier de la Légion d’honneur 2018,
  • Award René et André Duquesne, Comité de Paris Ligue Contre le Cancer 2018 ;
  • Award « Coups d’élan » Fondation Schueller-Bettencourt, 2016 ;
  • Award Raymond Rosen, Fondation pour la Recherche Médicale 2016 ;
  • Award Charles Oberling June 2015;
  • Elected fellow of the European Academy of Cancer Sciences, 2014;
  • Prime for excellent scientific activity (PEDR) 2012-present;
  • Award Inserm Research 2012; Trophée « Une équipe à l’honneur »,
  • Association pour la Recherche sur le Cancer 2008;
  • Award René Turpin of cancer research, French Academy of Science 2004;
  • Award young researcher Ligue Nationale Contre le Cancer, département des Yvelines 1998;
  • Young researcher, Fondation pour La Recherche Médicale 1994;
  • Laureate of medical school University Paris 7, Bichat, silver medal 1994;
  • Award Eugène et Amélie Dupuis French academy of science 1993;
  • Award Foundation For Advanced Cancer, The Molecular Basis of Human Cancer, Frederick, Maryland 1992



ORCID : 0000-0002-5687-0334

ISI Web of Science 2020, H-factor = 73, Citations >24,000. 200 original articles, 66 reviews or commentaries, 10 book chapters

Scientific summary

Hepatocellular carcinoma (HCC) is one of the leading causes of death by cancer worldwide. It is mainly developed on cirrhosis due to chronic hepatitis B and C, metabolic and alcoholic liver diseases in western countries. In contrast, hepatocellular adenomas are rare benign liver tumors frequently developed in women after oral contraception. Recent advances in molecular classification and dissection of genetic and epigenetic drivers have increased our knowledge of the molecular diversity of benign and malignant liver tumors. Using genomic approaches, we identified several new oncogenes and tumor suppressor genes and we described a molecular classification of hepatocellular adenomas that is used in clinical routine. Recently, using sequencing, we identified TERT promoter mutations activating telomerase as the most important mechanism of malignant transformation of both adenoma in carcinoma and of cirrhotic nodules in carcinoma. We also found new etiological factors predisposing to liver tumor development and new drug targets.

Image d’exemple